Arcturus Therapeutics (ARCT) Misses Q1 EPS by 90c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($2.15), $0.90 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $2.13 million versus the consensus estimate of $2.54 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance